Skip to main content
Clinical Trials/NCT07581288
NCT07581288Not yet recruitingNot Applicable

Quantitative Hormonal Biomarkers of Uterine Cancer Progression in Patients With Abnormal Uterine Bleeding

University of British Columbia1 site in 1 country50 target enrollmentStarted: May 1, 2026Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
50
Locations
1

Study Overview

Brief Summary

The investigators will obtain urine hormone results and validated menstrual bleeding score from people experiencing abnormal uterine bleeding. The investigators will evaluate satisfaction and ease of use of Mira monitor. The investigators will measure recruitment rate, attrition and cycle collection completeness of data. The investigators will evaluate menstrual health literacy at baseline and at the conclusion of the study.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
35 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 35 years and older
  • Have experienced AUB

Exclusion Criteria

  • Currently pregnant or become pregnant during their participation
  • Previous surgeries impairing the menstrual cycle (e.g. hysterectomy, bilateral oophorectomy)
  • Currently or in the previous 3 months on medications that are known to impair or stimulate ovulation (e.g. oral contraceptives, ovulation stimulants, hormone replacement, etc.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Aline Talhouk

Assistant Professor

University of British Columbia

Study Sites (1)

Loading locations...

Similar Trials